Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 19 09 2018
accepted: 08 04 2019
entrez: 6 6 2019
pubmed: 6 6 2019
medline: 6 2 2020
Statut: epublish

Résumé

Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder primarily affecting children and adolescents. It can lead to chronic pain, bony deformities and fractures. The pathophysiology of CNO is incompletely understood. Scientific evidence suggests dysregulated expression of pro- and anti-inflammatory cytokines to be centrally involved. Currently, treatment is largely based on retrospective observational studies and expert opinion. Treatment usually includes nonsteroidal anti-inflammatory drugs and/or glucocorticoids, followed by a range of drugs in unresponsive cases. While randomised clinical trials are lacking, retrospective and prospective non-controlled studies suggest effectiveness of TNF inhibitors and bisphosphonates. The objective of the Bayesian consensus meeting was to quantify prior expert opinion. Twelve international CNO experts were randomly chosen to be invited to a Bayesian prior elicitation meeting. Results showed that a typical new patient treated with pamidronate would have an 84% chance of improvement in their pain score relative to baseline at 26 weeks and an 83% chance on adalimumab. Experts thought there was a 50% chance that a new typical patient would record a pain score of 28mm (pamidronate) to 30mm (adalimumab) or better at 26 weeks. There was a modest trend in prior opinion to indicate an advantage of pamidronate vs adalimumab, with a 68% prior chance that pamidronate is superior to adalimumab by some margin. However, it is clear that there is considerable uncertainty about the precise relative merits of the two treatments. The rarity of CNO leads to challenges in conducting randomised controlled trials with sufficient power to provide a definitive outcome. We address this using a Bayesian design, and here describe the process and outcome of the elicitation exercise to establish expert prior opinion. This opinion will be tested in the planned prospective CNO study. The process for establishing expert consensus opinion in CNO will be helpful for developing studies in other rare paediatric diseases.

Identifiants

pubmed: 31166977
doi: 10.1371/journal.pone.0215739
pii: PONE-D-18-27335
pmc: PMC6550371
doi:

Substances chimiques

Adalimumab FYS6T7F842
Pamidronate OYY3447OMC

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0215739

Subventions

Organisme : NIAMS NIH HHS
ID : R01 AR059703
Pays : United States
Organisme : Medical Research Council
ID : MR/J014079/1
Pays : United Kingdom
Organisme : Arthritis Research UK
ID : 21212
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M013510/1
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Stat Med. 2009 Nov 10;28(25):3049-67
pubmed: 19630097
Pediatrics. 2012 Nov;130(5):e1190-7
pubmed: 23071213
Nat Clin Pract Rheumatol. 2007 Dec;3(12):733-8
pubmed: 18037933
Pediatrics. 2005 Nov;116(5):1231-3
pubmed: 16264014
J Rheumatol. 2016 Nov;43(11):1956-1964
pubmed: 27585682
Pharm Stat. 2018 Jul;17(4):301-316
pubmed: 29603614
Pediatr Rheumatol Online J. 2009 Jan 12;7:2
pubmed: 19138427
Clin Immunol. 2015 Dec;161(2):300-7
pubmed: 26404542
Front Pediatr. 2017 Dec 01;5:256
pubmed: 29250517
Spine (Phila Pa 1976). 2010 Apr 1;35(7):E253-6
pubmed: 20228700
Arthritis Care Res (Hoboken). 2018 Aug;70(8):1228-1237
pubmed: 29112802
Stat Med. 2005 Dec 30;24(24):3805-21
pubmed: 16320265
Rheumatology (Oxford). 2010 Aug;49(8):1505-12
pubmed: 20430869
Rheumatol Int. 2016 Dec;36(12):1737-1745
pubmed: 27730289
PLoS One. 2015 Mar 30;10(3):e0120981
pubmed: 25822991
Rheumatology (Oxford). 2014 Nov;53(11):1973-6
pubmed: 24899664
J Rheumatol. 2017 Jul;44(7):1058-1065
pubmed: 28461645
Stat Med. 2014 Oct 30;33(24):4186-201
pubmed: 24957522
Clin Immunol. 2018 Nov;196:77-84
pubmed: 29723617
Clin Immunol. 2011 Dec;141(3):317-27
pubmed: 21925952
J Rheumatol. 2008 Apr;35(4):707-12
pubmed: 18381777
Curr Osteoporos Rep. 2017 Dec;15(6):542-554
pubmed: 29080202
J Pediatr. 2008 Apr;152(4):571-5
pubmed: 18346517
Eur J Pediatr. 2010 Sep;169(9):1105-11
pubmed: 20339868

Auteurs

A V Ramanan (AV)

Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol and Bristol Medical School, University of Bristol, Bristol, United Kingdom.

L V Hampson (LV)

Statistical Methodology and Consulting, Novartis Pharma AG, Basel, Switzerland.

H Lythgoe (H)

Department of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom.

A P Jones (AP)

Clinical Trials Research Centre, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.

B Hardwick (B)

Clinical Trials Research Centre, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.

H Hind (H)

Clinical Trials Research Centre, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.

B Jacobs (B)

Paediatrics, Royal National Orthopaedic Hospital, London, United Kingdom.

D Vasileiou (D)

Department of Mathematics and Statistics, Fylde College, Lancaster University, Lancaster, United Kingdom.

I Wadsworth (I)

Department of Mathematics and Statistics, Fylde College, Lancaster University, Lancaster, United Kingdom.

N Ambrose (N)

Rheumatology, University College Hospital, London, United Kingdom.

J Davidson (J)

Paediatric Rheumatology, Royal Hospital for Children, Glasgow, United Kingdom.

P J Ferguson (PJ)

Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America.

T Herlin (T)

Department of Paediatrics, Aarhus University, Aarhus, Denmark.

A Kavirayani (A)

Paediatric Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

O G Killeen (OG)

National Centre for Paediatric Rheumatology, Our Lady's Children Hospital, Crumlin, Dublin, Ireland.

S Compeyrot-Lacassagne (S)

Rheumatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.

R M Laxer (RM)

Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada.

M Roderick (M)

Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol and Bristol Medical School, University of Bristol, Bristol, United Kingdom.

J F Swart (JF)

Paediatric Rheumatology, University Medical Centre Utrecht, Utrecht, Netherlands.

C M Hedrich (CM)

Department of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.

M W Beresford (MW)

Department of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH